Pose any clinical, safety, or competitive question in plain language. Evidara searches the primary literature, reads it, and answers — from what it retrieved, flagging any claim it cannot source. An evidence engine, not a chatbot.
Resmetirom (a liver-directed THR-β agonist) showed significant histologic benefit in MASH: the pivotal phase 3 trial reported higher rates of NASH resolution and ≥1-stage fibrosis improvement vs placebo at 52 weeks PMID 38324483.
Safety was generally manageable; the most common signals were diarrhea and nausea, with FAERS surveillance consistent with the trial profile FAERS. Long-term outcome data remain limited NCT03900429.
You watch it work — every search and source is shown, so the answer is auditable, not a black box.
Type a question the way you'd ask a colleague — a drug, an indication, a competitor, a safety signal.
Evidara translates your question into expert literature queries and pulls live results from PubMed, trials, and FAERS.
It reads the retrieved evidence and synthesizes an answer grounded only in what it found — so it can't make claims up.
Every citation links to a PMID, NCT, or FAERS record — ready to verify, export, or defend to MLR.
Asks PubMed, Europe PMC, and ClinicalTrials.gov in real time and ranks what matters — no manual searching.
Every statement carries a PMID / NCT / FAERS source, each identifier checked against the source API and labelled verified or not. Identifiers the model wrote that we didn't supply are flagged, never passed off as citations.
Pull FAERS adverse-event signals for any drug and have them interpreted alongside the trial evidence.
Ask who's in a space and where the gaps are — pipeline, trials, and positioning, grounded in the record.
When a question deserves a full brief, launch a complete SLR, CI, payer, or regulatory chain in one click.
Drop key papers into an Evidence Basket — Impact-scored and GRADE-tagged — or share an answer as a public link.
The same grounded engine, tuned to how each function actually works.
Prep KOL engagements and congress with the latest evidence and cited, PMID-backed objection-handlers.
Build payer value narratives and answer evidence questions with traceable, defensible proof.
Track the landscape and surface gaps — pipeline, trials, and positioning, grounded in the record.
Run a rapid evidence scan or launch a full systematic review without ever leaving the chat.
PubMed, Europe PMC, and ClinicalTrials.gov for literature and trials, plus openFDA FAERS for post-market safety, and OpenAlex for the scholarly graph — queried live, every time.
No. Citations are rebuilt from the evidence actually retrieved that turn — an identifier the model writes itself is stripped and flagged as unverified, never promoted to a citation. Claims it cannot source are flagged rather than hidden, and human review is required before external use.
Yes — when a question warrants it, the chat surfaces a one-tap launch into a complete analysis chain (SLR, competitive intelligence, payer, regulatory, and more).
It's built for it: auditable searches, traceable citations, explicit limitation flags, and a human-review requirement before any clinical, regulatory, or investment use.
Evidence-grade answers in minutes — every unverified claim flagged. See what your literature actually says.
Start chatting — free →